ISPOR OUTLINES NEW STRATEGIC VISION AT 18th ANNUAL EUROPEAN CONGRESS

Published Nov 10, 2015

ISPOR UPDATES STRATEGY IN ITS 20th ANNIVERSARY YEAR 

Milan, Italy—November 10, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) outlined the organization’s updated strategic vision this morning during its member meeting at the 18th Annual European Congress in Milan, Italy. ISPOR President Daniel C. Malone, RPh, PhD and CEO Nancy Berg presented ISPOR’s new organizational strategy, an update of ISPOR’s Vision 2020, the current strategic plan. ISPOR’s new Mission Statement to promote health economics and outcomes research excellence to improve decision making for health globally is supported by five strategic pillars:
  1. Scientific and Research Excellence
  2. Member Engagement
  3. Education and Training
  4. Communication and Collaboration
  5. Organizational Values
“We are very excited to introduce ISPOR’s new strategic vision to our members,” noted Berg. “Our updated strategy was developed by ISPOR’s Strategic Planning Working Group and approved by the ISPOR Board with input from many members.” In his comments, Malone emphasized the Society’s commitment to strengthen the integrity, advancement, and understanding of health economics and outcomes research globally. Additional information on ISPOR’s updated strategic vision may be found at http://www.ispor.org/mission.asp. ISPOR’s 18th Annual European Congress may be followed on social media using the hashtag #ISPORMilan.

###

Related Stories

Promoting Fairness in Funding Decisions

Jun 24, 2026

Value in Health announced the publication of a special themed section of research papers that offer new tools to help health policy makers weigh fairness alongside cost-effectiveness when deciding which treatments and programs to fund.

Listening to Patients in the Real World

Jun 23, 2026

Value in Health, the official journal of ISPOR announced today the publication of an ISPOR Good Practices Report outlining 9 areas to strengthen the robustness, transparency, and feasibility of real-world patient-reported outcomes studies.

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×